LENZ Therapeutics, Inc.
LENZ
$20.44
-$0.83-3.90%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 150.00% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 150.00% | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 150.00% | -- | |||
| SG&A Expenses | 115.66% | 15.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 43.60% | 29.09% | |||
| Operating Income | -12.04% | 0.44% | |||
| Income Before Tax | -15.88% | 1.42% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.99% | -2.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.99% | -2.00% | |||
| EBIT | -12.04% | 0.44% | |||
| EBITDA | -11.43% | 0.34% | |||
| EPS Basic | -10.17% | 0.00% | |||
| Normalized Basic EPS | -14.00% | 3.34% | |||
| EPS Diluted | -10.17% | 0.00% | |||
| Normalized Diluted EPS | -14.00% | 3.34% | |||
| Average Basic Shares Outstanding | 1.64% | 2.01% | |||
| Average Diluted Shares Outstanding | 1.64% | 2.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||